科伦药业 (002422)
SICHUAN KELUN PHARMACEUTICAL CO., LTD.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 159805.34
- Circulating A-Shares(W): 130587.47
- Earnings Per Share(RMB): 0.7500
- Net Assets Per Share(RMB): 14.8354
- Operating Revenue(W RMB): 1327672.98
- Total Profit(W RMB): 164893.01
- Net Profit Attributable to Parent(W RMB): 120066.57
- Net Profit Growth Rate(%): -51.41
- Weighted Return on Equity(%): 5.1800
- Operating Cash Flow Per Share(RMB): 1.0540
- Undistributed Profit Per Share(RMB): 7.3855
- Capital Reserve Per Share(RMB): 5.4703
2. Main Business
The main business covers:
- Research, production and sales of 24 dosage forms of drugs, including large-volume injections (infusions), small-volume injections, sterile powder injections (including divided powder injections and freeze-dried powder injections), tablets, capsules, granules, oral liquids, and peritoneal dialysis solutions.
- Research, production and sales of antibiotic intermediates, active pharmaceutical ingredients (APIs), and pharmaceutical packaging materials.
3. Company Basic Information
- Company Name: Sichuan Kelun Pharmaceutical Co., Ltd.
- Listing Date: 2010-06-03
- Industry: Pharmaceutical Manufacturing
- Address: No. 36 Baihua West Road, Qingyang District, Chengdu City, Sichuan Province
- Website: www.kelun.com
- Company Profile: The predecessor of the issuer, Sichuan Kelun Pharmaceutical Factory Co., Ltd., was established on May 29, 2002. On July 5, 2003, with the approval of the Sichuan Provincial People's Government, Kelun Limited was wholly transformed into a joint stock company. The company was registered and established on September 28, 2003, by the Chengdu Administration for Industry and Commerce.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Ya'an State-owned Assets Operation Co., Ltd. | General Legal Person | 9698.32 | 7.43 |
| 2 | China Europe Healthcare Hybrid Securities Investment Fund A | Fund | 4006.24 | 3.07 |
| 3 | Hong Kong Securities Clearing Company Ltd. | Northbound Funds | 3472.80 | 2.66 |
| 4 | GF Multi-Factor Flexible Allocation Hybrid Securities Investment Fund | Fund | 2423.35 | 1.86 |
| 5 | ICBC Credit Suisse Frontier Healthcare Equity Securities Investment Fund A | Fund | 2000.00 | 1.53 |
| 6 | Huatai-PineBridge CSI 300 ETF | Fund | 1908.41 | 1.46 |
| 7 | E Fund CSI 300 Healthcare ETF | Fund | 1403.83 | 1.08 |
| 8 | Fullgoal Precision Healthcare Flexible Allocation Hybrid Securities Investment Fund A | Fund | 1094.75 | 0.84 |
| 9 | Yinhua CSI Innovative Pharmaceutical Industry ETF | Fund | 1092.31 | 0.84 |
| 10 | Penghua Ingenuity Selection Hybrid Securities Investment Fund A | Fund | 756.00 | 0.58 |
5. Concept Sectors
- Generic Drugs
- Helicobacter Pylori
- Hepatitis Concept
- Innovative Drugs
- Synthetic Biology
- Margin Trading & Securities Lending
- High-Performance Stocks
- Heavily Held by Funds
- Subject to Takeover Bid
- MSCI Constituent
- Spin-off Listing
- Funds Reducing Holdings
- Heavily Held by Northbound Funds
- Non-Cyclical Stocks
- CSI 100
- SZSE Value
- CSI Mid-Small Cap 100
- SME 100
- Mid-Cap Value
- SZSE 100
- SZSE 300
- SZSE Dividend
- Consumption 100
- Private Enterprise 100
- SZSE National Value
- SZSE Growth
- CSI 300
- SME 300
- CSI 200
- CSI 300 Non-Cyclical
- SZSE Innovation
- Innovation 100
- CSI 300 ESG
- SZSE 50
- SZSE Main Board 50
- CSI A100
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information